17099-Lung Cancer-NA-126

Lung Cancer

RESILIENT: A Randomized, Open Label Phase 3 Study of Irinotecan Liposome Injection (ONIVYDE�) versus Topotecan in Patients with Small Cell Lung Cancer Who Have Progressed on or after Platinum-based First-Line Therapy (MM-398-01-03-04)

  • Details

ClinicalTrials.gov ID: NCT03088813
Diagnosis Type: NA
USOR Number:

  • Address

4700 E Hale Parkway, Suite 400
Denver, CO 80220
P: (303) 321-0302

Search by practice name, trial titles, indicators and specific disease types.